Publication | Closed Access

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial

ObesityMetabolic SyndromeNutritionInsulin Glargine TreatmentsDiabetes ManagementHepatologyLiver PhysiologyDiabetesPharmacologyType 2Insulin ManagementHepatic FatFatty Liver DiseaseMedicineHealth Sciences